Pre-made Inotuzumab Ozogamicin benchmark antibody (Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC-2/SIGLEC2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Inotuzumab Ozogamicin benchmark antibody (Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC-2/SIGLEC2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-868-1mg	1mg	Inquiry
GMP-Bios-INN-868-10mg	10mg	Inquiry
GMP-Bios-INN-868-100mg	100mg	Inquiry
GMP-Bios-INN-868-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Inotuzumab Ozogamicin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate
INN Name	Inotuzumab Ozogamicin
Target	CD22
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG4 - kappa
VD LC	IgG4 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Wyeth Pharmaceuticals (Madison NJ USA) / Pfizer (New York NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0